• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Facing Cancer as an AYA and Navigating Fertility Preservation Choices

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles Carly Stafford Dixon, discusses how she approached fertility preservation after her diagnosis of primary mediastinal b-cell lymphoma, a rare blood cancer. Read More

What Patients Should Know About a Melanoma Diagnosis

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles Melanoma care varies by stage, with early cases being treated with surgery, whereas advanced disease often requires immunotherapy or targeted therapy. Read More

Answers to Frequently Asked Questions About Prostate Cancer Risk, Treatment

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles Dr. Kelly Stratton answers the most frequently asked questions in prostate cancer regarding risk for recurrence, progression and treatment options. Read More

Reflecting on my Son’s Graduation as a Previvor

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles As a Lynch syndrome previvor, I feel deep gratitude to witness my son’s graduation — a milestone my brother never lived to see with his own child. Read More

First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity. Read More

Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found. Read More
« Older Entries
Next Entries »

Recent Content

  • The Gift of a Good Cancer Nurse
  • FDA Approves First, Only Single-Pill Triple Combination for Treatment of Hypertension
  • Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL
  • ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer
  • Prepare Patients for Summer Travel
  • ASCO 2025: THP Without Carboplatin Shows Noninferior pCR Rates, Improved Tolerability in HER2+ Early Breast Cancer
  • Registration Open for NCPA 2025 Annual Convention
  • Pharmacists Take the Lead on Advanced Therapeutics
  • Because Ned Said: New Technology Helps Prevent Opioid Overdose
  • TERZO Trial Doses First Patient With Copiktra in Rare T-Cell Lymphoma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT